ArticleCureus2026
Metastatic Clear Cell Renal Cell Carcinoma Masquerading as Urinary Bladder Tumor: A Report of a Rare Case.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell renal cell carcinoma (ccRCC) is known to be the most common histological subtype of renal cell carcinoma, with a well-known potential for distant metastasis. Common metastatic sites are the lungs, liver, bones, and brain; however, metastasis to the urinary bladder is exceptionally rare. We describe a 64-year-old man with a history of high-grade ccRCC who developed painless gross hematuria six months after undergoing right radical nephrectomy. Cystoscopic evaluation revealed two polypoidal bladder masses. Histopathological and immunohistochemical analyses confirmed metastatic ccRCC (positive for carbonic anhydrase IX (CAIX), paired-box gene 8 (PAX8), and cluster of differentiation 10 (CD10)). The patient was managed by transurethral resection of bladder tumor (TURBT) followed by targeted therapy with sunitinib (37.5 mg). He remains disease-free at one-year follow-up. This case underscores the importance of considering metastatic recurrence in patients with a prior history of RCC who present with new-onset urinary tract symptoms. Although rare, bladder metastasis should be included in the differential diagnosis. The underlying mechanism remains speculative, with possible routes including hematogenous spread, retrograde venous dissemination, or direct seeding. ccRCC can metastasize to unusual sites, including the urinary bladder. Early recognition through comprehensive imaging and immunohistochemical evaluation is essential for timely diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.